Lonafarnib

Lonafarnib

200px
Names
IUPAC name 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide
Other names Sarasar (US), SCH 66336
Identifiers
CAS Number	193275-84-2 N
ChEMBL	ChEMBL298734 Y
ChemSpider	130645 Y
IUPHAR/BPS	8024
Jmol 3D model	Interactive image
KEGG	D04768 Y
PubChem	148195
UNII	IOW153004F Y
InChI InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1 Y Key: DHMTURDWPRKSOA-RUZDIDTESA-N Y InChI=1/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1 Key: DHMTURDWPRKSOA-RUZDIDTEBQ
SMILES O=C(N)N5CCC(CC(=O)N4CCC([C@@H]3c1c(Br)cc(Cl)cc1CCc2cc(Br)cnc23)CC4)CC5
Properties
Chemical formula	C27H31Br2ClN4O2
Molar mass	638.82164
Vapor pressure	{{{value}}}
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Lonafarnib is a farnesyltransferase inhibitor (FTI) that is being investigated in a human clinical trial as a potential treatment for progeria.

Lonafarnib is a synthetic tricyclic derivative of carboxamide with antineoplastic properties. As such, it is used primarily for cancer treatment. For those with progeria, research has shown that the drug reduces the prevalence of stroke and transient ischemic attack, and the prevalence and frequency of headaches while taking the medication. A phase II clinical trial was completed in 2012, which showed that a cocktail of drugs that included lonafarnib and two other drugs, met clinical efficacy endpoints that improved the height and diminished the rigidity of the bones of progeria patients.

See also

• Laminopathy

External links

• "Experimental Drug Is First To Help Kids With Premature-Aging Disease", NPR, September 24, 2012